{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:24:25Z","timestamp":1789698265175,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Recent studies have suggested that sodium-glucose co-transporter2 inhibitors go beyond their glycemic advantages to ameliorate the development of NAFLD. However, little research has been done on the underlying mechanisms. Here, we took deep insight into the effect of canagliflozin (CANA), one of the sodium-glucose co-transporter2 inhibitor, on the progression of NAFLD, and explored the molecular mechanisms. Our findings showed that CANA-treated ob\/ob and diabetic mice developed improved glucose and insulin tolerance, although their body weights were comparable or even increased compared with the controls. The CANA treatment ameliorated hepatic steatosis and lipid accumulation of free fatty acid\u2013treated AML12 cells, accompanied by decreased lipogenic gene expression and increased fatty acid \u03b2 oxidation\u2013related gene expression. Furthermore, inflammation and fibrosis genes decreased in the livers of CANA-treated ob\/ob and diabetic mice mice. FGF21 and its downstream ERK1\/2\/AMPK signaling decreased, whereas NLRP3-mediated pyroptosis increased in the livers of the ob\/ob and diabetic mice mice, which was reversed by the CANA treatment. In addition, blocking FGF21 or ERK1\/2 activity antagonized the effects of CANA on NLRP3-mediated pyroptosis in lipopolysaccharide plus nigericin-treated J774A.1 cells. We conclude that CANA treatment alleviated insulin resistance and the progression of NAFLD in ob\/ob and diabetic mice mice independent of the body weight change. CANA protected against the progression of NAFLD by inhibiting NLRP3-mediated pyroptosis and enhancing FGF21-ERK1\/2 pathway activity in the liver. These findings suggest the therapeutic potential of sodium-glucose co-transporter2 inhibitors in the treatment of NAFLD.<\/jats:p>","DOI":"10.1097\/hc9.0000000000000045","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T17:01:15Z","timestamp":1675962075000},"page":"e0045-e0045","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":33,"title":["Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1\/2 pathway"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-1317","authenticated-orcid":false,"given":"Shaohan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6404-7997","authenticated-orcid":false,"given":"Beibei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-4388","authenticated-orcid":false,"given":"Yingzi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-0352","authenticated-orcid":false,"given":"Ruojun","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-1838","authenticated-orcid":false,"given":"Tian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Fourth Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-3436","authenticated-orcid":false,"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5820-3199","authenticated-orcid":false,"given":"Yongzhen","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-1860","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-2367","authenticated-orcid":false,"given":"Fenping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3]]},"reference":[{"key":"R1-20240826","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1210\/jc.2018-00554","article-title":"Ectopic lipid deposition is associated with insulin resistance in postmenopausal women","volume":"103","author":"Abildgaard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20240826","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20240826","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R7-20240826","doi-asserted-by":"crossref","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","article-title":"Metabolic liver disease in diabetes\u2014from mechanisms to clinical trials","volume":"111s","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"107927","DOI":"10.1016\/j.diabres.2019.107927","article-title":"Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials","volume":"158","author":"Patoulias","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","article-title":"Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the Cardiology Community","volume":"144","author":"Nelson","year":"2021","journal-title":"Circulation"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"R12-20240826","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R13-20240826","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R14-20240826","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"key":"R15-20240826","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R18-20240826","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr Connect"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"R21-20240826","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41419-018-1004-0","article-title":"Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway","volume":"9","author":"Qiu","year":"2018","journal-title":"Cell Death Dis"},{"key":"R22-20240826","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2010.06.007","article-title":"Manipulation of host cell death pathways during microbial infections","volume":"8","author":"Lamkanfi","year":"2010","journal-title":"Cell Host Microbe"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41419-019-1761-4","article-title":"Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2018.01.017","article-title":"Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications","volume":"68","author":"Beier","year":"2018","journal-title":"J Hepatol"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"112108","DOI":"10.1016\/j.yexcr.2020.112108","article-title":"FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis","volume":"393","author":"Zeng","year":"2020","journal-title":"Exp Cell Res"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/dna.2019.5151","article-title":"Inhibition of the ox-LDL-induced pyroptosis by FGF21 of human umbilical vein endothelial cells through the TET2-UQCRC1-ROS pathway","volume":"39","author":"Chen","year":"2020","journal-title":"DNA Cell Biol"},{"key":"R27-20240826","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R28-20240826","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbrc.2017.08.031","article-title":"Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet","volume":"492","author":"Hira","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R29-20240826","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41419-020-2664-0","article-title":"Induction of ASC pyroptosis requires gasdermin D or caspase-1\/11-dependent mediators and IFN\u03b2 from pyroptotic macrophages","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis"},{"key":"R30-20240826","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in obesity and cancer: new insights","volume":"499","author":"Lu","year":"2021","journal-title":"Cancer Lett"},{"key":"R31-20240826","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/antiox11010136","article-title":"Phytochemicals from the cocoa shell modulate mitochondrial function, lipid and glucose metabolism in hepatocytes via activation of FGF21\/ERK, AKT, and mTOR pathways","volume":"11","author":"Rebollo-Hernanz","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R32-20240826","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrgastro.2017.35","article-title":"NAFLD: a critical role for the NLRP3 inflammasome in NASH","volume":"14","author":"Thomas","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R33-20240826","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J Hepatol"},{"key":"R34-20240826","doi-asserted-by":"crossref","first-page":"663039","DOI":"10.3389\/fendo.2021.663039","article-title":"Exenatide attenuates non-alcoholic steatohepatitis by inhibiting the pyroptosis signaling pathway","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol"},{"key":"R35-20240826","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"R36-20240826","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"R37-20240826","doi-asserted-by":"crossref","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"R38-20240826","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R39-20240826","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R40-20240826","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/nu12051316","article-title":"Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD","volume":"12","author":"Worm","year":"2020","journal-title":"Nutrients"},{"key":"R41-20240826","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diab Endocrinol"},{"key":"R42-20240826","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"R43-20240826","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/db18-0304","article-title":"Pancreatic \u03b2-cell rest replenishes insulin secretory capacity and attenuates diabetes in an extreme model of obese type 2 diabetes","volume":"68","author":"Boland","year":"2019","journal-title":"Diabetes"},{"key":"R44-20240826","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/oby.2012.59","article-title":"Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R45-20240826","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPAR\u03b1","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"key":"R46-20240826","article-title":"Hepatic CPT1A facilitates liver-adipose cross-talk via induction of FGF21 in mice","author":"Sun","year":"2021","journal-title":"Diabetes"},{"key":"R47-20240826","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"R48-20240826","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/en.2010-1262","article-title":"Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance","volume":"153","author":"Hale","year":"2012","journal-title":"Endocrinology"},{"key":"R49-20240826","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"R50-20240826","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:05:46Z","timestamp":1724684746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000045","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"2022-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}